A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Brand Name :
N/A
Synonyms :
abicipar pegol
Class :
Ophthalmic, VEGF Inhibitors, Macular Degeneration Agents
Brand Name :
N/A
Synonyms :
abicipar pegol
Class :
Ophthalmic, VEGF Inhibitors, Macular Degeneration Agents
Age-related Neovascular Macular DegenerationÂ
FDA Approval Pending for exudative age-related macular degeneration (AMD)
Not suggested Â
Refer to adult dosingÂ
Actions and Spectrum Â
The action of abicipar pegol involves binding to VEGF-A (vascular endothelial growth factor (VEGF) and preventing it from interacting with its receptors on blood vessels.
None
Black Box Warning:Â
NoneÂ
Contraindication/Caution:Â Â Â
None
Pregnancy consideration:    Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category. Â
Pharmacology Â
The purpose of abicipar pegol is to bind with and block the function of VEGF-A. Â
abicipar pegol helps treat neovascular age-related macular degeneration by inhibiting VEGF-A, which helps stop the development of new blood vessels and lessens vascular leakage.Â
PharmacodynamicsÂ
The pharmacodynamic effect of abicipar pegol is its ability to reduce angiogenesis in the eye.Â
PharmacokineticsÂ
Limited information available on ADME
Administration Â
abicipar pegol is administered through intravitreal injection i.e., injected directly into the vitreous humor of the eye.Â
Patient information leafletÂ
Generic Name: abicipar pegol (FDA Approval Pending)Â
Why do we use abicipar pegol?Â
abicipar pegol is primarily used in the treatment of neovascular (wet) age-related macular degeneration (AMD).Â